Key Highlights
• Crinetics shares surged approximately 100% in pre-market trading to $84.08, up from a prior close of $42.03.
• Vertex Pharmaceuticals agreed to acquire Crinetics for $85.00 per share in cash, valuing the deal at approximately $10.0 billion in total equity value.
• The acquisition includes Crinetics' commercialized acromegaly therapy PALSONIFY and Phase 3 pipeline candidate atumelnant, with combined peak sales potential exceeding $5 billion.
• The transaction is backed by $4.5 billion in committed bridge financing from Bank of America and Morgan Stanley, and is expected to close in the third quarter of 2026.
Vertex to Acquire Endocrine-Focused Biotech at Premium
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) shares nearly doubled in pre-market trading after Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a definitive agreement to acquire the company for $85.00 per share in cash, representing a roughly 100% premium to Crinetics' prior closing price. The deal values Crinetics at approximately $10.0 billion in total equity value, or approximately $8.8 billion net of estimated cash acquired.
Crinetics is a San Diego-based commercial-stage pharmaceutical company focused on discovering, developing and commercializing novel therapeutics for endocrine diseases. The company's marketed medicine, PALSONIFY, received FDA approval in September 2025 as the first and only once-daily oral therapy for adults with acromegaly, a rare hormonal disorder affecting an estimated 20,000 diagnosed patients in the United States. The drug has since gained approval from the European Medicines Agency and is under review by additional global regulators.
The acquisition also brings Vertex atumelnant, Crinetics' most advanced pipeline candidate, a once-daily oral ACTH receptor antagonist currently in Phase 3 development for congenital adrenal hyperplasia, a rare genetic condition with 17,000 addressable patients in the U.S. The companies said the combined assets carry the potential to generate more than $5 billion in peak annual revenue, with the transaction expected to become accretive to Vertex's non-GAAP operating income in 2029.
Deal Structure and Strategic Rationale
Under the terms of the agreement, Vertex will finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing from Bank of America and Morgan Stanley. Morgan Stanley and Lazard are serving as financial advisors to Vertex, while J.P. Morgan Securities and Leerink Partners are advising Crinetics on the transaction.
Vertex Chief Executive Officer Reshma Kewalramani said Crinetics represents a strong strategic fit given its focus on serious diseases in specialty markets with significant unmet need, adding that the company sees potential for atumelnant to set a new standard of care for patients managing congenital adrenal hyperplasia. Crinetics shares traded at $84.08 in pre-market activity, within a range of $41.39 to $44.11 in the prior session, with the stock's market capitalization near $4.43 billion prior to the announcement.
The transaction was unanimously approved by both companies' boards of directors and remains subject to customary closing conditions, including regulatory approvals and approval by Crinetics shareholders, with completion expected in the third quarter of 2026.
Conclusion
Crinetics' pre-market surge reflects the substantial premium Vertex is paying to add a commercialized rare-disease therapy and a late-stage pipeline asset to its portfolio. Investors are likely to watch for shareholder approval progress and regulatory clearance milestones as the deal moves toward its expected close later this year.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...